GlassScriptPhysician profile
Megan E Grote
NPI 1215552161
$3,641.24
in general payments reported to CMS, 2019-2025
42 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $957 · 2023: $461 · 2024: $877 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.19 |
| Education | $218.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $402.78 | 2022-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $392.24 | 2021-2024 | Krazati |
| Janssen Scientific Affairs, LLC | $319.60 | 2023-2024 | Balversa, Erleada, Imbruvica |
| Abbvie INC. | $298.13 | 2022-2025 | |
| Seagen INC. | $162.97 | 2022-2023 | Padcev |
| Astellas Pharma US INC | $150.50 | 2022-2025 | Vyloy, Xospata |
| Jazz Pharmaceuticals INC. | $149.25 | 2022 | |
| Stemline Therapeutics INC. | $140.41 | 2024 | Orserdu |
| Karyopharm Therapeutics INC. | $137.51 | 2022-2024 | Xpovio |
| Genentech USA, INC. | $129.03 | 2021-2025 | Venclexta, Tecentriq, Polivy |
| Alexion Pharmaceuticals, INC. | $124.98 | 2021 | |
| Novocure INC. | $124.92 | 2021 | |
| Coherus Oncology, INC. | $109.47 | 2021 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2024 | |
| Genentech, INC. | $76.37 | 2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $60.68 | 2024-2025 | |
| Genmab U.S., INC. | $50.94 | 2023-2025 | Epkinly |
| Genzyme Corporation | $50.14 | 2023-2025 | |
| Octapharma USA, INC. | $49.73 | 2023-2025 | Octagam Immune Globulin (Human) |
| Taiho Oncology, INC. | $47.12 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $46.28 | 2024-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $46.04 | 2024-2025 | Tagrisso, Enhertu |
| Pfizer INC. | $45.50 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $40.90 | 2025 | |
| Merck Sharp & Dohme LLC | $35.09 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.58 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.59 | 2024-2025 | |
| Trisalus Life Sciences, INC. | $28.02 | 2025 | Trinav Infusion System |
| Pharming Healthcare, INC. | $27.19 | 2023 | Ruconest |
| Janssen Biotech, INC. | $24.74 | 2023-2025 | Rybrevant, Tecvayli, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $22.16 | 2025 | Iclusig |
| Syndax Pharmaceuticals, INC. | $20.88 | 2025 | |
| Celgene Corporation | $20.53 | 2025 | Reblozyl |
| Amgen INC. | $19.96 | 2022 | |
| Blueprint Medicines Corporation | $19.55 | 2025 | Ayvakit |
| Cti Biopharma Corp. | $16.94 | 2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $16.89 | 2024 | Qinlock |
| Ferring Pharmaceuticals INC. | $15.39 | 2025 | Adstiladrin |
| Exelixis INC. | $15.32 | 2023 | Cabometyx |
| Tersera Therapeutics LLC | $15.13 | 2024 | Zoladex |
| Lilly USA, LLC | $11.95 | 2022 | |
| Pharmaand Gmbh | $11.85 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Grote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.